Next Article in Journal
Identification of KIF11 as a Novel Target in Meningioma
Next Article in Special Issue
Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
Previous Article in Journal
18F-FDG-PET Can Predict Microvessel Density in Head and Neck Squamous Cell Carcinoma
Previous Article in Special Issue
Automated Quantification of Extranuclear ERα Using Phosphor-Integrated Dots for Predicting Endocrine Therapy Resistance in HR+/HER2 Breast Cancer
Open AccessArticle

CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma

1
EA3842 CAPTuR, Faculty of Medicine, University of Limoges, 2 Rue du Docteur Marcland, 87025 Limoges, France
2
Department of Medical Oncology, Limoges University Hospital, 2 rue Martin Luther King, 87042 Limoges, France
3
Bioinformatics Team, BISCEM Platform, CBRS, University of Limoges, 2 rue du Docteur Marcland, 87025 Limoges, France
4
EA7500 PEREINE, University of Limoges, 123 av. Albert Thomas, 87060 Limoges, France
5
Department of Neurosurgery, Limoges University Hospital, 2 rue Martin Luther King, 87042 Limoges, France
6
Department of Neuropathology and INSERM U1051, Hospital Saint Eloi—Gui de Chauliac, 80 av. Augustin Fliche, 34090 Montpellier, France
7
Department of Pathology, Limoges University Hospital, 2 rue Martin Luther King, 87042 Limoges, France
8
Department of Immunology, Limoges University Hospital, 2 rue Martin Luther King, 87042 Limoges, France
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2019, 11(4), 544; https://doi.org/10.3390/cancers11040544
Received: 8 February 2019 / Revised: 30 March 2019 / Accepted: 12 April 2019 / Published: 15 April 2019
(This article belongs to the Collection Cancer Biomarkers)
The aim of this study was to identify relevant biomarkers for the prognosis of glioma considering current molecular changes such as IDH mutation and 1p19q deletion. Gene expression profiling was performed using the TaqMan Low Density Array and hierarchical clustering using 96 selected genes in 64 patients with newly diagnosed glioma. The expression dataset was validated on a large independent cohort from The Cancer Genome Atlas (TCGA) database. A differential expression panel of 26 genes discriminated two prognostic groups regardless of grade and molecular groups of tumors: Patients having a poor prognosis with a median overall survival (OS) of 23.0 ± 9.6 months (group A) and patients having a good prognosis with a median OS of 115.0 ± 6.6 months (group B) (p = 0.007). Hierarchical clustering of the glioma TCGA cohort supported the prognostic value of these 26 genes (p < 0.0001). Among these genes, CHI3L1 and NTRK2 were identified as factors that can be associated with IDH status and 1p/19q co-deletion to distinguish between prognostic groups of glioma from the TCGA cohort. Therefore, CHI3L1 associated with NTRK2 seemed to be able to provide new information on glioma prognosis. View Full-Text
Keywords: glioma; IDH status; CHI3L1; NTRK2; prognosis glioma; IDH status; CHI3L1; NTRK2; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Deluche, E.; Bessette, B.; Durand, S.; Caire, F.; Rigau, V.; Robert, S.; Chaunavel, A.; Forestier, L.; Labrousse, F.; Jauberteau, M.-O.; Durand, K.; Lalloué, F. CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma. Cancers 2019, 11, 544.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop